Pulmatrix, Inc. (PULM) Just Reaches 52 Week Low?

March 14, 2018 - By Peter Erickson

The stock of Pulmatrix, Inc. (NASDAQ:PULM) hit a new 52-week low and has $1.23 target or 3.00 % below today’s $1.27 share price. The 5 months bearish chart indicates high risk for the $26.73 million company. The 1-year low was reported on Mar, 14 by Barchart.com. If the $1.23 price target is reached, the company will be worth $801,780 less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock.

The stock decreased 11.20% or $0.1602 during the last trading session, reaching $1.2698. About 482,786 shares traded or 25.87% up from the average. Pulmatrix, Inc. (NASDAQ:PULM) has risen 15.00% since March 14, 2017 and is uptrending. It has underperformed by 1.70% the S&P500.

Analysts await Pulmatrix, Inc. (NASDAQ:PULM) to report earnings on March, 16. After $-0.22 actual earnings per share reported by Pulmatrix, Inc. for the previous quarter, Wall Street now forecasts 22.73 % negative EPS growth.

More important recent Pulmatrix, Inc. (NASDAQ:PULM) news were published by: Marketwatch.com which released: “Pulmatrix Inc.” on May 03, 2017, also Prnewswire.com published article titled: “Pulmatrix Reports 2017 Financial Results; Provides 2018 Outlook on Pulmonary …”, Seekingalpha.com published: “Pulmatrix: The Best Biotech Buyout Target Out There?” on September 18, 2017. More interesting news about Pulmatrix, Inc. (NASDAQ:PULM) was released by: Prnewswire.com and their article: “Pulmatrix Announces First Subject Dosed in Phase 1 Clinical Trial of Pulmazole …” with publication date: February 12, 2018.

Pulmatrix, Inc., a clinical stage biopharmaceutical company, engages in developing inhaled therapies to address serious pulmonary diseases using its inhaled Small Particles Easily Respirable and Emitted technology. The company has market cap of $26.73 million. The company??s proprietary product pipeline focuses on advancing treatments for rare diseases, including PUR1900, an inhaled anti-fungal for patients with cystic fibrosis, as well as PUR1500, an inhaled product for the treatment of idiopathic pulmonary fibrosis (IPF). It currently has negative earnings. It is also developing PUR0200, a branded generic in clinical development for chronic obstructive pulmonary disease.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: